Altimmune (ALT)

• Market cap: $505M
• 1 day: -1.14%
• 5 days: -11.86%
• 1 month: -9.72%
• 3 months: -53.57%
• 6 months: -36.12%
• Year to date: -25.93%
• 1 year: -50.48%
• 5 years: -82.03%
• 10 years: -99.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 57